A total of 109 subjects with presumed MASH and qualifying baseline alanine transaminase (ALT) and imaging analysis were randomized to receive DA-1241 50 mg, DA-1241 100 mg alone, DA-1241 100 mg with a ...
On December 18, 2024, MetaVia Inc. (NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated ...
SEOUL, South Korea--(BUSINESS WIRE)--Dong-A ST (KRX: 170900) today announced that it successfully completed the proof-of-concept study for ‘DA-1241,’ an investigational first-in-class small molecule ...
MetaVia (MTVA) announced positive top-line 16-week results from the two-part Phase 2a clinical trial in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH. Part 1 of this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results